A notable example is lung cancer, where, after treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), some clones become highly resistant to TKIs, poised for proliferation when given the opportunity (Roper et al., 2020). Here, EGFR is linked to lung cancer.